Cadonilimab

Phase 3Monoclonal antibody

SShanghai Pharmaceuticals Holding Co., Ltd

It is used to treat severe cases of a serious inflammatory condition called cytokine release syndrome, which can occur as a severe side effect when certain cancer immunotherapy treatments activate the immune system too strongly.[1] Cadonilimab is currently being investigated across 52 indications[3], with its most advanced program in Phase 3.[1]

Cadonilimab is one of 958 small molecule programs targeting Pancreatic Neoplasm. It is currently in Phase 3.

Indications

Total Trials

Active Trials

957

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic NeoplasmActive, not recruiting

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

Urinary Bladder CarcinomaActive, not recruiting

Colorectal CarcinomaActive, not recruiting

Esophageal Squamous Cell CarcinomaActive, not recruiting

Clear Cell Renal CarcinomaActive, not recruiting

Nasopharyngeal CarcinomaActive, not recruiting

Unspecified Peripheral T-Cell LymphomaActive, not recruiting

Lung CancerActive, not recruiting

Bile Duct AdenocarcinomaActive, not recruiting

Pancreatic NeoplasmPhase 2

Active, not recruiting

Gastroesophageal Junction AdenocarcinomaPhase 3

Active, not recruiting

Urinary Bladder CarcinomaPhase 2

Active, not recruiting

Colorectal CarcinomaPhase 2

Active, not recruiting

Esophageal Squamous Cell CarcinomaPhase 2

Active, not recruiting

Clear Cell Renal CarcinomaPhase 2

Active, not recruiting

Nasopharyngeal CarcinomaPhase 3

Active, not recruiting

Unspecified Peripheral T-Cell LymphomaPhase 1

Active, not recruiting

Lung CancerPhase 2

Active, not recruiting

Bile Duct AdenocarcinomaPhase 2

Active, not recruiting

Showing 10 of 52 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Cadonilimab

SShanghai Pharmaceuticals Holding Co., Ltd

Phase 3

1 2

Tecentriq

Roche

Preclinical

36 3

Megace

Bristol-Myers Squibb

Preclinical

4 4

Lexiscan

Astellas

Preclinical

1 5

Adenocard

Astellas

Preclinical

1 6

Zolymbus

AbbVie

Preclinical

1 7

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 8

Paracetamol

GSK

Preclinical

1 9

QS21

MMemorial Sloan Kettering Cancer Center

Preclinical

3 10

Fentanyl Citrate

IINSYS Therapeutics Inc

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1/2Not yet recruiting

Nasopharyngeal Carcinoma

NCT05898256

Q4 2026

Phase 3Active, not recruiting

Nasopharyngeal Carcinoma

NCT06664983

Phase 2Not yet recruiting

Endometrial Cancer

NCT06066216

Phase 2Recruiting

Cervical Adenocarcinoma

NCT06654011

Phase 1Active, not recruiting

Hepatocellular Carcinoma

NCT05644379

Recruiting

Cervical Cancer

NCT06140589

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma8 trials

Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases

Recruiting·SSun Yat-sen University·N/A·NCT06265350·80 enrolled

Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 1·NCT05856864·30 enrolled

A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence

Terminated·GGuangxi Medical University·Phase 2·NCT06851104·45 enrolled

Show 5 more trials

A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma

Active, not recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 1·NCT05644379·30 enrolled

AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)

Unknown status·SSun Yat-sen University·Phase 2·NCT05578430·54 enrolled

Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma

Recruiting·HHunan Cancer Hospital·Phase 2·NCT06406634·30 enrolled

A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)

Recruiting·AAkeso·Phase 1/2·NCT06530251·280 enrolled

Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

Unknown status·FFirst Affiliated Hospital of Guangxi Medical University·Phase 1/2·NCT06040177·30 enrolled

Cervical Cancer6 trials

Induction Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT06511726·29 enrolled

Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical Cancer

Recruiting·FFujian Cancer Hospital··NCT06140589·200 enrolled

Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer

Recruiting·ZZhongnan Hospital·Phase 2·NCT05817214·35 enrolled

Show 3 more trials

Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors

Not yet recruiting·WWomen's Hospital School Of Medicine Zhejiang University·Phase 2·NCT05824494·58 enrolled

A Prospective Real-world Study of Cadonilimab in Patients With Recurrent or Metastatic Cervical Cancer

Not yet recruiting·GGang Chen (101199)··NCT06155422·670 enrolled

Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer

Recruiting·TTongji Hospital·Phase 2·NCT06289751·50 enrolled

Non-Small Cell Lung Cancer6 trials

A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer

Recruiting·GGuangzhou Institute of Respiratory Disease·Phase 2·NCT06331650·30 enrolled

A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed Immunotherapy

Recruiting·XXin-Hua Xu·Phase 2·NCT06467500·48 enrolled

Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)

Active, not recruiting·SShanghai Chest Hospital·Phase 1/2·NCT05816499·50 enrolled

Show 3 more trials

Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative

Recruiting·QQian Chu·Phase 2·NCT06001151·49 enrolled

To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)

Recruiting·GGuangzhou Institute of Respiratory Disease·Phase 2·NCT06341660·30 enrolled

Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain Metastases

Unknown status·SSecond Affiliated Hospital of Nanchang University·Phase 2·NCT05812534·36 enrolled

Nasopharyngeal Carcinoma4 trials

Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)

Active, not recruiting·SSun Yat-sen University·Phase 3·NCT05587374·490 enrolled

TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma

Active, not recruiting·SSun Yat-sen University·Phase 3·NCT06664983·84 enrolled

Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma

Unknown status·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT05790200·30 enrolled

Show 1 more trial

Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma

Not yet recruiting·GGuangxi Medical University·Phase 1/2·NCT05898256·20 enrolled

Treatment3 trials

Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC

Unknown status·—·Phase 2·NCT05901584·30 enrolled

A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 1·NCT05644392·30 enrolled

Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients

Not yet recruiting·—·Phase 1/2·NCT06577961·37 enrolled

42 more indications

Gastric Cancer3 trials

Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial

Not yet recruiting·NNanfang Hospital, Southern Medical University·Phase 2·NCT06310473·30 enrolled

Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05974059·20 enrolled

RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer

Not yet recruiting·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT06492317·20 enrolled

First-line Treatment3 trials

AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

Recruiting·HHarbin Medical University·Phase 2·NCT06196697·50 enrolled

Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients

Recruiting·ZZhejiang Cancer Hospital·Phase 1/2·NCT06650332·90 enrolled

Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC

Recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT06424821·54 enrolled

Gastroesophageal Junction Adenocarcinoma3 trials

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

Recruiting·RRemeGen Co., Ltd.·Phase 2/3·NCT06221748·90 enrolled

A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting·AAkeso·Phase 3·NCT06341335·506 enrolled

Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting·AAkeso·Phase 2·NCT05960955·90 enrolled

Triple-Negative Breast Cancer2 trials

SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)

Recruiting·UUnknown Sponsor·Phase 2·NCT06401005·51 enrolled

Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer

Not yet recruiting·SShengjing Hospital·Phase 2·NCT06202313·128 enrolled

Esophageal Squamous Cell Carcinoma2 trials

Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)

Recruiting·AAkeso·Phase 2·NCT07263919·90 enrolled

Efficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

Enrolling by invitation·FFirst Affiliated Hospital of Ningbo University·N/A·NCT06715501·20 enrolled

Endometrial Cancer2 trials

Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer

Active, not recruiting·SSun Yat-sen University·Phase 2·NCT05824481·32 enrolled

Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT06066216·45 enrolled

Colorectal Cancer2 trials

Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer

Unknown status·FFujian Cancer Hospital·Phase 2·NCT05839470·20 enrolled

Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer

Recruiting·—·Phase 2·NCT05815290·50 enrolled

Fruquintinib2 trials

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

Recruiting·HHuazhong University of Science and Technology·Phase 2·NCT06168786·40 enrolled

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

Recruiting·LLiu Huang·N/A·NCT06551207·80 enrolled

Radiotherapy1 trial

AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06472037·30 enrolled

Liver Cancer1 trial

Ligufalimab and Cadonilimab in Advanced Liver Cancers

Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT06789848·64 enrolled

Neoadjuvant Therapy1 trial

Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Completed·SSun Yat-sen University·Phase 2·NCT06138496·39 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma

Unknown status·XXuekui Liu·Phase 2·NCT06023875·30 enrolled

Esophageal Cancer1 trial

Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006)

Active, not recruiting·SSun Yat-sen University·Phase 2·NCT06143748·46 enrolled

Cervical Adenocarcinoma1 trial

IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Trial

Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT06654011·25 enrolled

Salivary Gland Carcinoma1 trial

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Recruiting·PPeking Union Medical College·Phase 2·NCT06145308·39 enrolled

mRNA Vaccine1 trial

A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC

Not yet recruiting·AAkeso·Phase 1·NCT06913218·60 enrolled

Portal Hypertension1 trial

TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study

Recruiting·FFei Gao·Phase 2·NCT05882370·30 enrolled

Patients With Advanced Solid Tumors1 trial

A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

Recruiting·SShanghai Pharmaceuticals Holding Co., Ltd·Phase 1/2·NCT05944224·63 enrolled

Lung Cancer1 trial

Cadonilimab Monotherapy as Neoadjuvant Therapy for Resectable II-IIIA Squamous Cell Lung Cancer

Not yet recruiting·TThe First Hospital of Jilin University·Phase 2·NCT05784974·37 enrolled

Breast Cancer1 trial

Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer

Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT06367088·27 enrolled

Locally Advanced1 trial

A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC

Recruiting·AAkeso·Phase 3·NCT06617416·560 enrolled

Leptomeningeal Metastasis1 trial

Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis

Recruiting·GGuangzhou Medical University·Phase 1/2·NCT06762080·36 enrolled

Microsatellite Instability1 trial

Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer

Not yet recruiting·AAkeso·Phase 3·NCT07412613·386 enrolled

Locally-advanced Rectal Cancer1 trial

Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer

Completed·SShenzhen People's Hospital·Phase 2·NCT05792735·27 enrolled

Concurrent Chemoradiotherapy1 trial

Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLC

Active, not recruiting·FFudan University·Phase 2·NCT06448910·41 enrolled

Bladder Cancer1 trial

Cadonilimab Plus Nab-Paclitaxel for Recurrent or Metastatic Muscle Invasive Bladder Cancer

Unknown status·TTianjin Medical University Second Hospital·Phase 2·NCT06009848·20 enrolled

Adenocarcinoma1 trial

A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma

Recruiting·AAkeso·Phase 3·NCT07023315·760 enrolled

Metastatic Melanoma1 trial

Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure

Not yet recruiting·HHunan Cancer Hospital·Phase 2·NCT06327698·30 enrolled

Glioblastoma1 trial

Treatment of Recurrent Glioblastoma With Fractionated Radiotherapy Combined With Cadonilimab

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT05737368·11 enrolled

Metastatic1 trial

SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC

Not yet recruiting·TThe First People's Hospital of Changzhou·Phase 2·NCT05732662·25 enrolled

Endometrial Carcinoma1 trial

Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma

Recruiting·SShandong Cancer Hospital and Institute·Phase 2·NCT06532539·30 enrolled

Ivonescimab1 trial

A Study of Ivonescimab in First-Line ES-SCLC

Recruiting·AAkeso·Phase 2·NCT07245446·180 enrolled

Systemic Therapy1 trial

AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy

Recruiting·FFudan University·Phase 2·NCT06494995·52 enrolled

Intrahepatic Cholangiocarcinoma1 trial

Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

Not yet recruiting·SShanghai Zhongshan Hospital·Phase 2·NCT07243951·75 enrolled

Neoadjuvant Treatment1 trial

XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer

Recruiting·—·Phase 2·NCT05815303·92 enrolled

Ovarian Cancer1 trial

SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases

Active, not recruiting·ZZhang Tao·Phase 1/2·NCT06940921·26 enrolled

Chemotherapy1 trial

Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC

Recruiting·SSichuan University·Phase 2·NCT06769971·80 enrolled

Soft Tissue Sarcoma1 trial

A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma

Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT06367075·53 enrolled

Refractory Malignant Solid Tumors1 trial

Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors

Unknown status·PPeking University Third Hospital·Phase 1/2·NCT05915481·60 enrolled

Resectable Hepatocellular Carcinoma1 trial

A Phase Ib Open-label, Randomized Trial Evaluating Neoadjuvant Ateganosine and Cadonilimab in Resectable Hepatocellular Carcinoma

Not yet recruiting·UUniversity of Texas Southwestern Medical Center·Phase 1·NCT07446257·60 enrolled

Colorectal Cancer Stage IV1 trial

Cadonilimab (Bispecific Anti-PD-1/CTLA-4 Antibody) for PD-1/PD-L1 Blockade-refractory, Microsatellite Instability-high (MSI-H) or Mismatch Repair-deficient (dMMR), Advanced Colorectal Cancer: a Single Group, Multicenter, Phase 2 Trial

Active, not recruiting·SSun Yat-sen University·Preclinical·NCT05426005·28 enrolled

Unspecified1 trial

Cadonilimab Combined With RT in LACC Patients Ineligible for CCRT

Not yet recruiting·RRuijin Hospital·Phase 2·NCT07450963·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 80 trial records for Cadonilimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cadonilimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cadonilimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Pharmaceuticals Holding Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Programmed Cell Death Protein 1 Inhibitor; Cytotoxic T-Lymphocyte Protein 4 Inhibitor[2]
Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: SShanghai Pharmaceuticals Holding Co., Ltd

Cadonilimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

Hepatocellular Carcinoma8 trials

Cervical Cancer6 trials

Non-Small Cell Lung Cancer6 trials

Nasopharyngeal Carcinoma4 trials

Treatment3 trials

Gastric Cancer3 trials

First-line Treatment3 trials

Gastroesophageal Junction Adenocarcinoma3 trials

Triple-Negative Breast Cancer2 trials

Esophageal Squamous Cell Carcinoma2 trials

Endometrial Cancer2 trials

Colorectal Cancer2 trials

Fruquintinib2 trials

Radiotherapy1 trial

Liver Cancer1 trial

Neoadjuvant Therapy1 trial

Head and Neck Squamous Cell Carcinoma1 trial

Esophageal Cancer1 trial

Cervical Adenocarcinoma1 trial

Salivary Gland Carcinoma1 trial

mRNA Vaccine1 trial

Portal Hypertension1 trial

Patients With Advanced Solid Tumors1 trial

Lung Cancer1 trial

Breast Cancer1 trial

Locally Advanced1 trial

Leptomeningeal Metastasis1 trial

Microsatellite Instability1 trial

Locally-advanced Rectal Cancer1 trial

Concurrent Chemoradiotherapy1 trial

Bladder Cancer1 trial

Adenocarcinoma1 trial

Metastatic Melanoma1 trial

Glioblastoma1 trial

Metastatic1 trial

Endometrial Carcinoma1 trial

Ivonescimab1 trial

Systemic Therapy1 trial

Intrahepatic Cholangiocarcinoma1 trial

Neoadjuvant Treatment1 trial

Ovarian Cancer1 trial

Chemotherapy1 trial

Soft Tissue Sarcoma1 trial

Refractory Malignant Solid Tumors1 trial

Resectable Hepatocellular Carcinoma1 trial

Colorectal Cancer Stage IV1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News